Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.8201
-0.0486-5.60%
Post-market: 0.8001-0.0199-2.43%19:50 EDT
Volume:487.21K
Turnover:393.17K
Market Cap:11.48M
PE:-0.07
High:0.8467
Open:0.8467
Low:0.7600
Close:0.8687
Loading ...

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Benzinga
·
14 Feb

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

PR Newswire
·
14 Feb

Moleculin Biotech Gets FDA Nod for Phase 3 Trial

TIPRANKS
·
13 Feb

BRIEF-Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia

Reuters
·
13 Feb

Moleculin Biotech Inc - FDA Allows Reduction in Size of Moleculin's Phase 3 Trial

THOMSON REUTERS
·
13 Feb

Moleculin Receives Positive FDA Guidance for Acceleration of Its Registration-Enabling Miracle Trial for R/R Acute Myeloid Leukemia (Aml)

THOMSON REUTERS
·
13 Feb

Moleculin Biotech Inc - Amended Protocol Allows Unblinding of Data at 45 Subjects

THOMSON REUTERS
·
13 Feb

Moleculin Biotech Inc - First Unblinding Expected in Second Half of 2025

THOMSON REUTERS
·
13 Feb

Moleculin Biotech Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
12 Feb

Moleculin Biotech downgraded to Hold from Buy at Maxim

TIPRANKS
·
12 Feb

Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial

MT Newswires Live
·
12 Feb

Moleculin Biotech Gains European Approval for Phase 3 Trial

TIPRANKS
·
11 Feb

BRIEF-Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial

Reuters
·
11 Feb

Moleculin Biotech receives first approval in Europe for AML trial recruiting

TIPRANKS
·
11 Feb

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the Miracle Phase 3 R/R Acute Myeloid Leukemia (Aml) Pivotal Trial

THOMSON REUTERS
·
11 Feb

Moleculin Biotech Inc - First Subject Treatment in Miracle Trial Expected Q1 2025

THOMSON REUTERS
·
11 Feb

Moleculin Biotech Launches MIRACLE Study for AML

TIPRANKS
·
27 Jan

Moleculin Biotech (MBRX) Gets a Buy from Roth MKM

TIPRANKS
·
12 Jan

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in Aml, Phase 3 Data Readouts in 2025 & 2026

THOMSON REUTERS
·
08 Jan

Moleculin Biotech: on Track to Begin Dosing of Annamycin in Combination With Cytarabine for Treatment of R/R Aml in Q1 2025

THOMSON REUTERS
·
08 Jan